NasdaqGS:EXEL

Stock Analysis Report

Executive Summary

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States.

Snowflake

Fundamentals

Flawless balance sheet and good value.


Similar Companies

Share Price & News

How has Exelixis's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: EXEL's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.7%

EXEL

2.5%

US Biotechs

0.9%

US Market


1 Year Return

-8.9%

EXEL

10.8%

US Biotechs

16.8%

US Market

Return vs Industry: EXEL underperformed the US Biotechs industry which returned 10.8% over the past year.

Return vs Market: EXEL underperformed the US Market which returned 16.8% over the past year.


Shareholder returns

EXELIndustryMarket
7 Day0.7%2.5%0.9%
30 Day-2.0%11.8%4.5%
90 Day-20.0%7.6%6.2%
1 Year-8.9%-8.9%11.8%10.8%19.4%16.8%
3 Year0%0%18.6%14.8%47.5%38.0%
5 Year836.9%836.9%5.8%0.8%62.0%44.1%

Price Volatility Vs. Market

How volatile is Exelixis's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Exelixis undervalued compared to its fair value and its price relative to the market?

31.0%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: EXEL ($16.49) is trading below our estimate of fair value ($23.9)

Significantly Below Fair Value: EXEL is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: EXEL is good value based on its PE Ratio (8.1x) compared to the Biotechs industry average (17.5x).

PE vs Market: EXEL is good value based on its PE Ratio (8.1x) compared to the US market (18.2x).


Price to Earnings Growth Ratio

PEG Ratio: EXEL is good value based on its PEG Ratio (0.5x)


Price to Book Ratio

PB vs Industry: EXEL is overvalued based on its PB Ratio (3.1x) compared to the US Biotechs industry average (2.9x).


Next Steps

Future Growth

How is Exelixis forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?

16.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EXEL's forecast earnings growth (16.4% per year) is above the savings rate (2.7%).

Earnings vs Market: EXEL's earnings (16.4% per year) are forecast to grow faster than the US market (14.4% per year).

High Growth Earnings: EXEL's earnings are forecast to grow, but not significantly.

Revenue vs Market: EXEL's revenue (13.2% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: EXEL's revenue (13.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: EXEL's Return on Equity is forecast to be low in 3 years time (18.8%).


Next Steps

Past Performance

How has Exelixis performed over the past 5 years?

74.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EXEL has a high level of non-cash earnings.

Growing Profit Margin: EXEL's current net profit margins (64%) are higher than last year (49.4%).


Past Earnings Growth Analysis

Earnings Trend: EXEL has become profitable over the past 5 years, growing earnings by 74.3% per year.

Accelerating Growth: EXEL's earnings growth over the past year (66.2%) is below its 5-year average (74.3% per year).

Earnings vs Industry: EXEL earnings growth over the past year (66.2%) underperformed the Biotechs industry 86.5%.


Return on Equity

High ROE: EXEL's Return on Equity (38.2%) is considered high.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Exelixis's financial position?


Financial Position Analysis

Short Term Liabilities: EXEL's short term assets ($972.1M) exceeds its short term liabilities ($141.1M)

Long Term Liabilities: EXEL's short term assets ($972.1M) exceeds its long term liabilities (40.1M)


Debt to Equity History and Analysis

Debt Level: EXEL is debt free.

Reducing Debt: EXEL currently has no debt however we can't compare to 5 years ago as we have no data for that period.

Debt Coverage: EXEL has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: EXEL has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: EXEL has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if EXEL's debt is covered by short term assets.


Next Steps

Dividend

What is Exelixis's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate EXEL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate EXEL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EXEL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EXEL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EXEL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Exelixis's salary, the management and board of directors tenure and is there insider trading?

4.3yrs

Average management tenure


CEO

Michael Morrissey (58yo)

9.3yrs

Tenure

US$7,977,535

Compensation

Dr. Michael M. Morrissey, Ph.D., has been the Chief Executive Officer and President of Exelixis, Inc. since July 2010. Dr. Morrissey served as the President of Research and Development at Exelixis Inc. sin ...


CEO Compensation Analysis

Compensation vs Market: Michael's total compensation ($USD7.98M) is about average for companies of similar size in the US market ($USD6.77M).

Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.


Management Age and Tenure

4.3yrs

Average Tenure

58yo

Average Age

Experienced Management: EXEL's management team is considered experienced (4.3 years average tenure).


Board Age and Tenure

17.1yrs

Average Tenure

65.5yo

Average Age

Experienced Board: EXEL's board of directors are seasoned and experienced ( 17.1 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$1,018,00011 May 19
Lance Willsey
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares50,000
Max PriceUS$20.36
SellUS$750,60304 May 19
Christopher Senner
EntityIndividual
Role
Chief Financial Officer
Executive VP & CFO
Shares36,261
Max PriceUS$20.70
SellUS$95,13728 Feb 19
Patrick Haley
EntityIndividual
Shares4,272
Max PriceUS$22.27
SellUS$5,494,90620 Feb 19
Charles Cohen
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares248,180
Max PriceUS$22.41
SellUS$285,29001 Dec 18
Jeffrey Hessekiel
EntityIndividual
Role
Chief Legal Officer
Executive VP
Shares14,818
Max PriceUS$19.91
SellUS$173,18301 Dec 18
Christopher Senner
EntityIndividual
Role
Chief Financial Officer
Executive VP & CFO
Shares8,791
Max PriceUS$19.70

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Management Team

  • Gisela Schwab (62yo)

    President of Product Development & Medical Affairs and Chief Medical Officer

    • Tenure: 13.8yrs
    • Compensation: US$3.60m
  • Stelios Papadopoulos (71yo)

    Co-Founder & Chairman

    • Tenure: 21.8yrs
    • Compensation: US$421.05k
  • Michael Morrissey (58yo)

    CEO, President & Director

    • Tenure: 9.3yrs
    • Compensation: US$7.98m
  • Peter Lamb (58yo)

    Executive VP of Scientific Strategy & Chief Scientific Officer

    • Tenure: 12.8yrs
    • Compensation: US$3.17m
  • Susan Hubbard

    Executive Vice President of Public Affairs & Investor Relations

    • Tenure: 2.9yrs
  • Jeffrey Hessekiel (50yo)

    Executive VP

    • Tenure: 5.8yrs
    • Compensation: US$2.73m
  • Chris Senner (51yo)

    Executive VP & CFO

    • Tenure: 4.3yrs
    • Compensation: US$3.39m
  • Jon Berndt

    Vice President of Sales

    • Tenure: 4.2yrs
  • Gregg Bernier

    Vice President of Marketing

    • Tenure: 4.2yrs
  • Dana Aftab

    Executive Vice President of Business Operations

    • Tenure: 3.8yrs

Board Members

  • Jack Wyszomierski (63yo)

    Independent Director

    • Tenure: 15.8yrs
    • Compensation: US$406.05k
  • Charlie Cohen (68yo)

    Independent Director

    • Tenure: 24yrs
    • Compensation: US$408.70k
  • Stelios Papadopoulos (71yo)

    Co-Founder & Chairman

    • Tenure: 21.8yrs
    • Compensation: US$421.05k
  • Michael Morrissey (58yo)

    CEO, President & Director

    • Tenure: 9.3yrs
    • Compensation: US$7.98m
  • George Poste (75yo)

    Independent Director

    • Tenure: 15.3yrs
    • Compensation: US$396.05k
  • Lance Willsey (57yo)

    Independent Director

    • Tenure: 22.6yrs
    • Compensation: US$384.70k
  • George Scangos (71yo)

    Independent Director

    • Tenure: 23.1yrs
    • Compensation: US$375.70k
  • Vincent Marchesi (83yo)

    Independent Director

    • Tenure: 18.5yrs
    • Compensation: US$391.05k
  • Alan Garber (63yo)

    Independent Director

    • Tenure: 14.8yrs
    • Compensation: US$390.70k
  • José Baselga (59yo)

    Member of Scientific Advisory Board

    • Tenure: 12.8yrs

Company Information

Exelixis, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Exelixis, Inc.
  • Ticker: EXEL
  • Exchange: NasdaqGS
  • Founded: 1994
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$5.010b
  • Shares outstanding: 303.85m
  • Website: https://www.exelixis.com

Number of Employees


Location

  • Exelixis, Inc.
  • 1851 Harbor Bay Parkway
  • Alameda
  • California
  • 94502
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EXELNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDApr 2000
EX9DB (Deutsche Boerse AG)YesCommon StockDEEURApr 2000
0IJOLSE (London Stock Exchange)YesCommon StockGBUSDApr 2000

Biography

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company’s products includ ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/20 23:36
End of Day Share Price2019/11/20 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.